Peddock Capital Advisors’s Niagen Bioscience NAGE Stock Holding History

Peddock Capital Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,380	Closed	-$16K	–	291
2020 Q4	$16K	Buy	+3,380	New	+$16.5K	0.01%	219
2020 Q1	–	Sell	-3,380	Closed	-$15K	–	238
2019 Q4	$15K	Buy	+3,380	New	+$12K	0.01%	209
2019 Q2	–	Sell	-3,380	Closed	-$14K	–	235
2019 Q1	$14K	Hold	3,380	–	–	0.01%	208
2018 Q4	$12K	Hold	3,380	–	–	0.01%	216
2018 Q3	$15K	Hold	3,380	–	–	0.01%	217
2018 Q2	$13K	Hold	3,380	–	–	0.01%	220
2018 Q1	$14K	Hold	3,380	–	–	0.01%	214
2017 Q4	$20K	Hold	3,380	–	–	0.01%	206
2017 Q3	$15K	Hold	3,380	–	–	0.01%	214
2017 Q2	$13K	Buy	+3,380	New	+$10.7K	0.01%	220

Other funds holding NAGE

YRHAM

Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Peddock Capital Advisors's NAGE Position: Q1 2021 in Review

Peddock Capital Advisors sold out of Niagen Bioscience (NAGE) in Q1 2021, closing a stake of 3,380 shares — an estimated $16K sold.

Peddock Capital Advisors first reported a position in NAGE in Q2 2017 and held it in 10 quarters. The position peaked at $20K in Q4 2017. 96 funds tracked by Wall St. Rank hold NAGE as of Q1 2021.

Peddock Capital Advisors reported no remaining Niagen Bioscience position as of Q1 2021 after selling out during the quarter.
Peddock Capital Advisors sold 3,380 Niagen Bioscience shares in Q1 2021, an estimated $16K.
Peddock Capital Advisors first reported a position in Niagen Bioscience in Q2 2017 and held it in 10 quarters.
Peddock Capital Advisors's Niagen Bioscience position peaked at $20K in Q4 2017.
96 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2021.

Based on Peddock Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.